JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

Kodu・Aktsiate loetelu・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Suletud

SektorTervishoid

42.83 -1.27

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

42.76

Max

43.38

Põhinäitajad
By Trading Economics
Sissetulek	-1.1B 1.3B
Müük	1.1B 12B
P/E Sektori keskmine	17.888 37.461
Aktsiakasum	1.46
Dividenditootlus	5.64
Kasumimarginaal	10.702
Töötajad	34,100
EBITDA	-1.2B 3.3B

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+19.1% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	5.64% 2.33%
Järgmine tulemuste avaldamine	30. okt 2025
Järgmine dividendimakse kuupäev	3. nov 2025

Turustatistika
By TradingEconomics
Turukapital	-4.6B 91B
Eelmine avamishind	44.1
Eelmine sulgemishind	42.83

Uudiste sentiment

By Acuity

20%

80%

32 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

N/A / 50.57 Toetus ja vastupanu

Bristol-Myers Squibb Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. okt 2025, 12:32 UTC

Omandamised, ülevõtmised, äriostud

Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion

31. juuli 2025, 11:14 UTC

Tulu

Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q

2. juuni 2025, 11:48 UTC

Suurimad hinnamuutused turgudel

BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion

10. okt 2025, 16:19 UTC

Omandamised, ülevõtmised, äriostud

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

10. okt 2025, 11:02 UTC

Omandamised, ülevõtmised, äriostud

Bristol-Myers Squibb to Pay $1.5B in Cash at Closing to Acquire Orbital >BMY

10. okt 2025, 11:01 UTC

Omandamised, ülevõtmised, äriostud

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio With Acquisition of Orbital Therapeutics

4. aug 2025, 11:59 UTC

Tulu

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

31. juuli 2025, 11:54 UTC

Tulu

Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb Cuts 2025 View To Adj EPS $6.35-Adj EPS $6.65 Vs Prior View $6.70-$7.00 >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 2Q Adjusted Gross Margin 72.6% >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 2Q Adj EPS $1.46 >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 2Q International Revenue Rose 10% to $3.75B >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb Raises 2025 View To Rev $46.5B-$47.5B From Prior View $45.8B-$46.8B >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Expected Continued Generic Impact Across Remainder of Legacy Portfolio, as Well as Impacts From U.S. Medicare Part D Redesign >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: In Back Half of Year, Focused on Advancing Transformational Medicines and Delivering on Our Growth Portfolio and Important Pipeline Opportunities to Shape Our Growth Trajectory >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: Raised 2025 Rev Guidance Reflecting Strength of Growth Portfolio, Better-Than-Expected Legacy Portfolio Sales in 2Q and Favorable Impact of About $200M Related to Foreign Exchange Rates >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: Latest 2Q Includes Net Impact of Loss of 57c/Shr Due to Acquired IPRD Charge Associated With BioNtech Strategic Partnership >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Breyanzi, Reblozyl and Camzyos, and Reflects Continued Strength of Cobenfy >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 2Q Legacy Portfolio Rev Fell 14% to $5.67B >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 2Q Gross Margin 72.5% >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 2Q Rev $12.27B >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Beats Earnings Expectations. It's Still Optimistic About New Schizophrenia Drug. -- Barrons.com

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb: Revised 2025 Adj EPS Guidance Inclusive of BioNTech Acquired IPRD Chg in 2Q >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 2Q U.S. Revenue Fell 3% to $8.52B >BMY

31. juuli 2025, 10:59 UTC

Tulu

Bristol Myers Squibb 2Q EPS 64c >BMY

12. juuni 2025, 14:20 UTC

Omandamised, ülevõtmised, äriostud

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

13. mai 2025, 16:48 UTC

Omandamised, ülevõtmised, äriostud

2seventy bio: Bristol Myers Squibb Completes Acquisition of 2seventy

12. mai 2025, 22:14 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. mai 2025, 18:45 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

Võrdlus sarnastega

Hinnamuutus

Bristol-Myers Squibb Co. Prognoos

Hinnasiht

By TipRanks

19.1% tõus

12 kuu keskmine prognoos

Keskmine 51 USD 19.1%

Kõrge 65 USD

Madal 34 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Bristol-Myers Squibb Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

19 ratings

Osta

Hoia

Müü

Põhineb 19 analüütiku instrumendi Bristol-Myers Squibb Co. aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 50.57Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

32 / 373 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.